Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells

European Journal of Clinical Investigation

Volumn 44, Issue 6, 2014, Pages 539-548

  Llorente Cortés, Vicenta ^a   De Gonzalo Calvo, David ^a   Orbe, Josune ^b   Páramo, Jose Antonio ^b   Badimon, Lina ^a  

^a Institut Català de Ciències Cardiovasculars   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Atherosclerosis; Inflammation; Interleukin 4; Mononuclear leucocytes; Peripheral arterial disease

Indexed keywords

ALPHA INTEGRIN; ALPHA INTEGRIN M; INTERLEUKIN 4; RNA; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; CD11B ANTIGEN; ITGAM PROTEIN, HUMAN; MESSENGER RNA; TLR2 PROTEIN, HUMAN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DOPPLER FLOWMETRY; GENE EXPRESSION; HUMAN; HYPERTENSION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA EXTRACTION; SUBCLINICAL FEMORAL ARTERY ATHEROSCLEROSIS; SYSTOLIC BLOOD PRESSURE; AGED; CHEMISTRY; FEMORAL ARTERY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

AGED; ANTIGENS, CD11B; ATHEROSCLEROSIS; FEMORAL ARTERY; GENE EXPRESSION; HUMANS; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2;

EID: 84900798536     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12267     Document Type: Article

References (60)

1. Annex BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol 2013;10:387-96.
2. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-92.
3. Gornik HL, Beckman JA. Cardiology patient page. Peripheral arterial disease. Circulation 2005;111:e169-72.
4. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
5. Mohler ER III. Peripheral arterial disease: identification and implications. Arch Intern Med 2003;163:2306-14.
6. Ouriel K. Peripheral arterial disease. Lancet 2001;358:1257-64.
7. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151:786.e1-10.
8. Stehouwer CD, Clement D, Davidson C, Diehm C, Elte JW, Lambert M et al. Peripheral arterial disease: a growing problem for the internist. Eur J Intern Med 2009;20:132-8.
9. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
10. Au TB, Golledge J, Walker PJ, Haigh K, Nelson M. Peripheral arterial disease - diagnosis and management in general practice. Aust Fam Physician 2013;42:397-400.
11. Gratchev A, Ovsiy I, Manousaridis I, Riabov V, Orekhov A, Kzhyshkowska J. Novel monocyte biomarkers of atherogenic conditions. Curr Pharm Des 2013;19:5859-64.
12. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol 2013;62:1541-51.
13. Fenyo IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology 2013;218:1376-84.
14. Gratchev A, Sobenin I, Orekhov A, Kzhyshkowska J. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology 2012;217:476-82.
15. Joehanes R, Johnson AD, Barb JJ, Raghavachari N, Liu P, Woodhouse KA et al. Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham Heart Study. Physiol Genomics 2012;44:59-75.
16. Stamova B, Xu H, Jickling G, Bushnell C, Tian Y, Ander BP et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 2010;41:2171-7.
17. Aziz H, Zaas A, Ginsburg GS. Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomic Med 2007;1:105-12.
18. Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, Holbrook B et al. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A 2005;102:3423-8.
19. Wang ZH, Zhang W, Gong HP, Guo ZX, Zhao J, Shang YY et al. Expression of STAMP2 in monocytes associates with cardiovascular alterations. Eur J Clin Invest 2010;40:490-6.
20. Wingrove JA, Daniels SE, Sehnert AJ, Tingley W, Elashoff MR, Rosenberg S et al. Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet 2008;1:31-8.
21. Bernal-López MR, Llorente-Cortés V, Calleja F, López-Carmona D, Mayas MD, Gómez-Huelgas R et al. Effect of different degrees of impaired glucose metabolism on the expression of inflammatory markers in monocytes of patients with atherosclerosis. Acta Diabetol 2013;50:553-62.
22. Bernal-López RM, Llorente-Cortés V, López-Carmona D, Mayas DM, Gómez-Huelgas R, Tinahones FJ et al. Modulation of human monocyte CD36 by type 2 diabetes mellitus and other atherosclerotic risk factors. Eur J Clin Invest 2011;41:854-62.
23. Llorente-Cortés V, Estruch R, Mena MP, Ros E, González MA, Fitó M et al. Effect of Mediterranean diet on the expression of pro-atherogenic genes in a population at high cardiovascular risk. Atherosclerosis 2010;208:442-50.
24. Ma J, Dempsey AA, Stamatiou D, Marshall KW, Liew CC. Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis 2007;191:63-72.
25. Heijink IH, Vellenga E, Borger P, Postma DS, de Monchy JG, Kauffman HF. Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells. Immunology 2002;107:316-24.
26. Timofeeva AV, Goryunova LE, Khaspekov GL, Kovalevskii DA, Scamrov AV, Bulkina OS et al. Altered gene expression pattern in peripheral blood leukocytes from patients with arterial hypertension. Ann N Y Acad Sci 2006;1091:319-35.
27. Maiwald S, Zwetsloot PP, Sivapalaratnam S, Dallinga-Thie GM. Monocyte gene expression and coronary artery disease. Curr Opin Clin Nutr Metab Care 2013;16:411-7.
28. Sternberg Z, Ghanim H, Gillotti KM, Tario JD Jr, Munschauer F, Curl R et al. Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood. Atherosclerosis 2013;229:338-47.
29. Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P et al. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res 2008;103:1402-9.
30. Luzina IG, Keegan AD, Heller NM, Rook GA, Shea-Donohue T, Atamas SP. Regulation of inflammation by interleukin-4: a review of "alternatives". J Leukoc Biol 2012;92:753-64.
31. May P. The low-density lipoprotein receptor-related protein 1 in inflammation. Curr Opin Lipidol 2013;24:134-7.
32. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest 2013;123:27-36.
33. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010;10:36-46.
34. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ et al. The association between the metabolic syndrome and peripheral, but not coronary, artery disease is partly mediated by endothelial dysfunction: the CODAM study. Eur J Clin Invest 2011;41:167-75.
35. Jacobs M, van Greevenbroek MMJ, van der Kallen CJH, Ferreira I, Blaak EE, Feskens EJM et al. Low-grade inflammation can partly explain the association between the metabolic syndorme and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009;39:437-44.
36. Correa CR, Dias-Melicio LA, Calvi SA, Lastoria S, Soares AM. Activation of monocytes and cytokine production in patients with peripheral atherosclerosis obliterans. J Inflamm (Lond) 2011;8:23.
37. Dopheide JF, Obst V, Doppler C, Radmacher MC, Scheer M, Radsak MP et al. Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease. Thromb Haemost 2012;108:1198-207.
38. Evans DC, Sileshi B, Zakaria AM, Giangiacomo D, Manson RJ, Lawson JH. Genomic modeling of atherosclerosis in peripheral arterial disease and its variant phenotype in patients with diabetes. Vascular 2008;16:225-35.
39. Fu S, Zhao H, Shi J, Abzhanov A, Crawford K, Ohno-Machado L et al. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses. BMC Genomics 2008;9:369.
40. Masud R, Shameer K, Dhar A, Ding K, Kullo IJ. Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease. J Clin Bioinforma 2012;2:6.
41. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003;163:1117-25.
42. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008;28:2108-14.
43. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010;207:1579-87.
44. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002;109:745-53.
45. Marino F, Guasti L, Tozzi M, Schembri L, Castiglioni L, Molteni E et al. Gene expression of adhesion molecules in endothelial cells from patients with peripheral arterial disease is reduced after surgical revascularization and pharmacological treatment. Int J Vasc Med 2013;2013:412761.
46. Chinetti-Gbaguidi G, Staels B. Macrophage polarization in metabolic disorders: functions and regulation. Curr Opin Lipidol 2011;22:365-72.
47. Martínez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009;27:451-83.
48. de Gonzalo-Calvo D, de Luxán-Delgado B, Martínez-Camblor P, Rodríguez-Gonzalez S, García-Macia M, Suárez FM et al. Chronic inflammation as predictor of 1-year hospitalization and mortality in elderly population. Eur J Clin Invest 2012;42:1037-46.
49. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5.
50. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011;10:365-76.
51. de Gonzalo-Calvo D, Fernández-García B, de Luxán-Delgado B, Rodríguez-González S, García-Macia M, Suárez FM et al. Long-term training induces a healthy inflammatory and endocrine emergent biomarker profile in elderly men. Age (Dordr) 2012;34:761-71.
52. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410-22.
53. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Aros F et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-90.
54. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62.
55. Revuelta-López E, Castellano J, Roura S, Gálvez-Monton C, Nasarre L, Benítez S et al. Hypoxia induces metalloproteinase-9 activation and human vascular smooth muscle cell migration through low-density lipoprotein receptor-related protein 1-mediated pyk2 phosphorylation. Arterioscler Thromb Vasc Biol 2013;33:2877-87.
56. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008;88:887-918.
57. Costales P, Castellano J, Revuelta-Lopez E, Cal R, Aledo R, Llampayas O et al. Lipopolysaccharide downregulates CD91/low-density lipoprotein receptor-related protein 1 expression through SREBP-1 overexpression in human macrophages. Atherosclerosis 2013;227:79-88.
58. Llorente-Cortés V, Royo T, Otero-Viñas M, Berrozpe M, Badimon L. Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. Cardiovasc Res 2007;74:526-36.
59. Handschug K, Schulz S, Schnurer C, Kohler S, Wenzel K, Teichmann W et al. Low-density lipoprotein receptor-related protein in atherosclerosis development: up-regulation of gene expression in patients with coronary obstruction. J Mol Med (Berl) 1998;76:596-600.
60. Sendra J, Llorente-Cortés V, Costales P, Huesca-Gómez C, Badimon L. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. Cardiovasc Res 2008;78:581-9.